Tracking defects caused by brain tumor mutation yields insight to advance targeted therapy
Friday, May 8, 2015 - 14:00
in Biology & Nature
Scientists have gained ground toward developing more targeted therapies for the most common childhood brain tumor. The findings involve the DDX3X gene. In 2012, other work highlighted DDX3X as a promising focus for efforts to develop targeted therapies against medulloblastoma. Such treatments target the genetic mistakes that give rise to the brain tumor’s four subtypes.